Niagen Bioscience(NAGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NAGE Niagen Bioscience

Post-Mkt 12-11 16:24:37 EST

6.63

+0.05

+0.76%

盘后6.63

+0.000.00%

16:10 EST

High6.66	Low6.51	Vol610.28K
Open6.56	D1 Closing6.58	Amplitude2.20%
Mkt Cap529.87M	Tradable Cap340.88M	Total Shares79.92M
T/O4.03M	T/O Rate1.19%	Tradable Shares51.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NAGE","market":"US","secType":"STK","nameCN":"Niagen Bioscience","latestPrice":6.63,"timestamp":1765486800000,"preClose":6.58,"halted":0,"volume":610279,"hourTrading":{"tag":"盘后","latestPrice":6.63,"preClose":6.63,"latestTime":"16:10 EST","volume":24403,"amount":161799.2475045,"timestamp":1765487404300},"delay":0,"floatShares":51414700,"shares":79919957,"eps":0.234893,"marketStatus":"Post-Mkt","change":0.05,"latestTime":"12-11 16:24:37 EST","open":6.56,"high":6.655,"low":6.51,"amount":4027735.1058,"amplitude":0.022036,"askPrice":6.7,"askSize":255,"bidPrice":6.55,"bidSize":43,"shortable":3,"etf":0,"ttmEps":0.234893,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":6.58,"preHourTrading":{"tag":"盘前","latestPrice":6.5983,"preClose":6.58,"latestTime":"09:23 EST","volume":79,"amount":521.395497,"timestamp":1765463031615},"postHourTrading":{"tag":"盘后","latestPrice":6.63,"preClose":6.63,"latestTime":"16:10 EST","volume":24403,"amount":161799.2475045,"timestamp":1765487404300},"volumeRatio":0.871664,"impliedVol":0.5875,"impliedVolPercentile":0.2097},"requestUrl":"/m/hq/s/NAGE/wiki","defaultTab":"wiki","newsList":[{"id":"2586440357","title":"Niagen Bioscience management to meet with Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2586440357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586440357?lang=en_us&edition=fundamental","pubTime":"2025-11-26 02:35","pubTimestamp":1764095741,"startTime":"0","endTime":"0","summary":"Meeting to be held in Chicago on December 3 hosted by Roth Capital. Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-management-to-meet-with-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-management-to-meet-with-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2584926062","title":"Niagen Bioscience Announces $10 Million Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926062","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926062?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:55","pubTimestamp":1763571341,"startTime":"0","endTime":"0","summary":"Nov 6 (Reuters) - Niagen Bioscience Inc ::*NIAGEN BIOSCIENCE ANNOUNCES $10 MILLION SHARE REPURCHASE PROGRAM  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202513:07:00.187 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD5NxnTV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2584265476","title":"Niagen Bioscience CFO Pamir Ozan Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584265476","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584265476?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:23","pubTimestamp":1763385834,"startTime":"0","endTime":"0","summary":"Ozan Pamir, Chief Financial Officer of Niagen Bioscience Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDLbZdDVx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Niagen Bioscience CFO Pamir Ozan Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2583942625","title":"Correction: Niagen Says Long COVID Trial Exploring Supplement Failed to Show 'Statistically Significant Differences' in Meeting Endpoints Versus Placebo Groups","url":"https://stock-news.laohu8.com/highlight/detail?id=2583942625","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583942625?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:40","pubTimestamp":1763048453,"startTime":"0","endTime":"0","summary":"Niagen Bioscience  said Wednesday that a clinical trial showed that daily supplement of its patented nicotinamide riboside Niagen did not show \"statistically significant differences\" in meeting primary or secondary endpoints in patients with long COVID-19 relative to placebo groups.The 58-participant placebo-controlled 24-week study showed that the supplement increased NAD+ co-enzyme levels up to 3.1-fold and improved functioning, fatigue, depression, and sleep quality, when compared to their baseline levels, in some individuals, the company said.The study's inconclusive results were \"likely due to the small sample size and high dropout rates,\" the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2583536862","title":"Niagen Bioscience announces results of Niagen supplementation in long COVID","url":"https://stock-news.laohu8.com/highlight/detail?id=2583536862","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583536862?lang=en_us&edition=fundamental","pubTime":"2025-11-13 10:25","pubTimestamp":1763000710,"startTime":"0","endTime":"0","summary":"Niagen Bioscience (NAGE) shared promising results from the first-of-its-kind clinical trial published today in The Lancet peer-reviewed journal eCl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-announces-results-of-niagen-supplementation-in-long-covid-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-announces-results-of-niagen-supplementation-in-long-covid-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2583580313","title":"Niagen Bioscience Reports Clinical Trial Shows Niagen Supplement Boosts NAD+ and Eases Long COVID Symptoms","url":"https://stock-news.laohu8.com/highlight/detail?id=2583580313","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583580313?lang=en_us&edition=fundamental","pubTime":"2025-11-13 08:52","pubTimestamp":1762995153,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. has announced results from the first-ever randomized controlled trial examining Niagen, the company's patented nicotinamide riboside  supplement, in individuals with long COVID. The findings, published in The Lancet's eClinicalMedicine journal, indicate that daily supplementation with Niagen significantly increased NAD+ levels and was associated with within-group improvements in executive functioning, fatigue, depression, and sleep quality compared to baseline. The 24-week, double-blind, placebo-controlled study involved 58 non-hospitalized adults experiencing persistent symptoms following COVID-19 infection. Results from this clinical trial have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL3DW3yZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2582688283","title":"We Think Niagen Bioscience's (NASDAQ:NAGE) Profit Is Only A Baseline For What They Can Achieve","url":"https://stock-news.laohu8.com/highlight/detail?id=2582688283","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582688283?lang=en_us&edition=fundamental","pubTime":"2025-11-11 18:34","pubTimestamp":1762857277,"startTime":"0","endTime":"0","summary":"Even though Niagen Bioscience, Inc. ( NASDAQ:NAGE ) posted strong earnings, investors appeared to be underwhelmed. We...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nage/niagen-bioscience/news/we-think-niagen-biosciences-nasdaqnage-profit-is-only-a-base","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nage/niagen-bioscience/news/we-think-niagen-biosciences-nasdaqnage-profit-is-only-a-base","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":[".IXIC","TQQQ","TSYW.SI","NAGE","FCF","BK4211","QID","QLD","USAW.SI","PSQ","NQmain","BK4121","USJW.SI","SQQQ","NVIW.SI","MNQmain"],"gpt_icon":1},{"id":"2581011203","title":"Niagen Bioscience Approves $10 Million Stock Buyback Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2581011203","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581011203?lang=en_us&edition=fundamental","pubTime":"2025-11-07 03:19","pubTimestamp":1762456756,"startTime":"0","endTime":"0","summary":"Niagen Bioscience  said Thursday its board authorized a stock buyback program of up to $10 million over about 24 months.The company may repurchase shares through open market or private transactions, depending on market conditions and legal requirements, it said.Price: 6.82, Change: -0.06, Percent Change: -0.94","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"1199485103","title":"Stock Track | Niagen Bioscience Soars 6.25% Following $10 Million Share Repurchase Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1199485103","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199485103?lang=en_us&edition=fundamental","pubTime":"2025-11-06 23:06","pubTimestamp":1762441565,"startTime":"0","endTime":"0","summary":"Shares of Niagen Bioscience (NAGE) are soaring 6.25% in early trading on Thursday, building on the momentum from pre-market activity. The surge comes in response to the company's announcement of a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NAGE"],"gpt_icon":0},{"id":"1171120965","title":"Stock Track | Niagen Bioscience Soars 6.25% on $10 Million Share Repurchase Program Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1171120965","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171120965?lang=en_us&edition=fundamental","pubTime":"2025-11-06 23:06","pubTimestamp":1762441564,"startTime":"0","endTime":"0","summary":"Shares of Niagen Bioscience (NAGE) are soaring 6.25% in pre-market trading on Thursday, following the company's announcement of a $10 million share repurchase program. This significant uptick...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NAGE"],"gpt_icon":0},{"id":"2581094432","title":"Niagen Bioscience Announces $10 Million Share Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2581094432","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581094432?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:29","pubTimestamp":1762439353,"startTime":"0","endTime":"0","summary":"Niagen Bioscience ( ($NAGE) ) has provided an announcement. On November 6, 2025, Niagen Bioscience announced that its Board of Directors approved a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/niagen-bioscience-announces-10-million-share-buyback?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/niagen-bioscience-announces-10-million-share-buyback?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"1149417785","title":"Stock Track | Niagen Bioscience Soars 6.10% Pre-market on $10 Million Share Repurchase Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1149417785","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149417785?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:46","pubTimestamp":1762436815,"startTime":"0","endTime":"0","summary":"Niagen Bioscience (NAGE) shares surged 6.10% in pre-market trading on Thursday, following the company's announcement of a $10 million share repurchase program. This strategic move has sparked...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NAGE"],"gpt_icon":0},{"id":"1105974537","title":"Stock Track | Niagen Bioscience Soars 6.10% Pre-market on $10 Million Share Buyback Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1105974537","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105974537?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:46","pubTimestamp":1762436814,"startTime":"0","endTime":"0","summary":"Shares of Niagen Bioscience (NAGE) surged 6.10% in pre-market trading on Thursday, following the company's announcement of a $10 million share repurchase program. This significant uptick reflects...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NAGE"],"gpt_icon":0},{"id":"2581222096","title":"BRIEF-Niagen Bioscience Announces $10 Million Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2581222096","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581222096?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:44","pubTimestamp":1762436674,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Announces $10 Million Share Repurchase ProgramNov 6 (Reuters) - Niagen Bioscience Inc NAGE.O:NIAGEN BIOSCIENCE ANNOUNCES $10 MILLION SHARE REPURCHASE PROGRAMSource text: ID:nBw6nTMLHaFurther company coverage: NAGE.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA6HQFMC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2581475709","title":"Niagen Bioscience Inc. Publishes Transcript of Third Quarter 2025 Earnings Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2581475709","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581475709?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:03","pubTimestamp":1762376623,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. has published the transcript of its Third Quarter 2025 Earnings Conference Call, which took place on Tuesday, November 4, 2025. The event was attended by key company executives, including Chief Executive Officer Rob Fried, Chief Financial Officer Ozan Pamir, and Senior Vice President of Scientific and Regulatory Affairs Dr. Andrew Shao, who joined for the Q&A session. During the call, management discussed the company's financial results for the third quarter of 2025, research and development updates, clinical trial plans and timing, and future regulatory filings. The expansion of Niagen products into new markets, business development opportunities, and investor interest were also highlighted. Management noted the company's ongoing commitment to innovation and market growth. \"We remain focused on advancing our clinical programs and expanding our product reach,\" stated the CEO. The CFO commented on financial performance, emphasizing the company's approach to future","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL5M4Xq4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2581748708","title":"Niagen Bioscience Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2581748708","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581748708?lang=en_us&edition=fundamental","pubTime":"2025-11-06 02:30","pubTimestamp":1762367400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NAGE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 13:30 ET (18:30 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE"],"gpt_icon":0},{"id":"2581177645","title":"Niagen Bioscience price target lowered to $14 from $16 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2581177645","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581177645?lang=en_us&edition=fundamental","pubTime":"2025-11-05 22:26","pubTimestamp":1762352814,"startTime":"0","endTime":"0","summary":"Canaccord lowered the firm’s price target on Niagen Bioscience (NAGE) to $14 from $16 and keeps a Buy rating on the shares. The firm said they post...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-price-target-lowered-to-14-from-16-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-price-target-lowered-to-14-from-16-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAGE"],"gpt_icon":0},{"id":"2581476060","title":"Niagen Bioscience Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2581476060","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581476060?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:01","pubTimestamp":1762293699,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc reports results for the quarter ended September 30 - Earnings SummaryNiagen Bioscience Inc NAGE.OQ reported quarterly adjusted earnings of 5 cents per share for the quarter ended","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL8N3WG3FG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2581762901","title":"Niagen Bioscience Inc. unveils investor presentation highlighting NAD+ market growth and product pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2581762901","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581762901?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:30","pubTimestamp":1762291800,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. released a corporate presentation highlighting its position as a leading authority on NAD+ with over 100 patents and a strong intellectual property portfolio. The company reported $124.7 million in revenue and $20.4 million in net income for the last twelve months ending in the third quarter of 2025. As of September 30, 2025, Niagen Bioscience reported $64.3 million in cash and no debt. The company's business is diversified across consumer health, IV and injectables, pharmaceuticals, and skincare, with significant revenue generated from its Tru Niagen supplement. Niagen Bioscience collaborates with leading research institutions and has an active pipeline of clinical trials, particularly in areas such as Parkinson's disease and ataxia. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, thi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL7sb60T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2581366762","title":"Niagen Bioscience Q3 sales beat estimates on strong e-commerce performance","url":"https://stock-news.laohu8.com/highlight/detail?id=2581366762","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581366762?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:28","pubTimestamp":1762291728,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Q3 sales beat estimates on strong e-commerce performanceOverviewNiagen Bioscience Q3 net sales rise 33%, beating analyst expectationsAdjusted EBITDA for Q3 increases 120%, reflecting","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL1N3WG1D8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0203347892.USD","BK4149","BK4121","LU0154245756.USD","BK4533","LU0203345920.USD","NAGE","LU0154245673.USD","BK4588","BK4567","CMI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.niagenplus.com","stockEarnings":[{"period":"1week","weight":0.0077},{"period":"1month","weight":-0.0732},{"period":"3month","weight":-0.316},{"period":"6month","weight":-0.5172},{"period":"1year","weight":-0.0194},{"period":"ytd","weight":0.2403}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":" ","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.043813},{"month":2,"riseRate":0.555556,"avgChangeRate":0.218645},{"month":3,"riseRate":0.333333,"avgChangeRate":0.069369},{"month":4,"riseRate":0.555556,"avgChangeRate":0.036039},{"month":5,"riseRate":0.5,"avgChangeRate":0.021036},{"month":6,"riseRate":0.6,"avgChangeRate":0.068253},{"month":7,"riseRate":0.5,"avgChangeRate":-0.007412},{"month":8,"riseRate":0.3,"avgChangeRate":-0.041379},{"month":9,"riseRate":0.3,"avgChangeRate":-0.054309},{"month":10,"riseRate":0.2,"avgChangeRate":-0.056092},{"month":11,"riseRate":0.7,"avgChangeRate":0.200397},{"month":12,"riseRate":0.3,"avgChangeRate":-0.020807}],"exchange":"NASDAQ","name":"Niagen Bioscience","nameEN":"Niagen Bioscience"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Niagen Bioscience(NAGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Niagen Bioscience(NAGE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Niagen Bioscience,NAGE,Niagen Bioscience股票,Niagen Bioscience股票老虎,Niagen Bioscience股票老虎国际,Niagen Bioscience行情,Niagen Bioscience股票行情,Niagen Bioscience股价,Niagen Bioscience股市,Niagen Bioscience股票价格,Niagen Bioscience股票交易,Niagen Bioscience股票购买,Niagen Bioscience股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Niagen Bioscience(NAGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Niagen Bioscience(NAGE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}